T. Yanagawa, Hideomi Watanabe, T. Shinozaki, K. Takagishi
{"title":"Usefulness of FDG PET in Primary Bone Tumors~!2009-05-15~!2009-12-18~!2010-03-25~!","authors":"T. Yanagawa, Hideomi Watanabe, T. Shinozaki, K. Takagishi","doi":"10.2174/1876525401002010019","DOIUrl":null,"url":null,"abstract":"Positron emission tomography (PET) using ( 18 F)fluorodeoxyglucose (FDG) is a useful modality to examine many kinds of tumors, including primary bone tumors. Malignant bone tumors show higher FDG accumulation than benign tumors and earlier reports mention that FDG-PET can differentiate malignancy from benignancy; however, some benign bone tumors present with high FDG accumulation, which increases false positive rates in FDG-PET. FDG accumulation reflects glucose metabolism and thereby FDG-PET can be used for staging malignant bone tumors, which require a large amount of glucose. Combined with conventional studies, such as magnetic resonance imaging (MRI) and scintigraphy, FDG-PET can more accurately decide the staging. Finally, FDG-PET is also applied to evaluate the chemotherapy response of malignant bone tumors and is expected to predict a patient's prognosis and to help to decide appropriate chemotherapy agents.","PeriodicalId":89634,"journal":{"name":"The Open bone journal","volume":"2 1","pages":"19-23"},"PeriodicalIF":0.0000,"publicationDate":"2010-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open bone journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876525401002010019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
Abstract
Positron emission tomography (PET) using ( 18 F)fluorodeoxyglucose (FDG) is a useful modality to examine many kinds of tumors, including primary bone tumors. Malignant bone tumors show higher FDG accumulation than benign tumors and earlier reports mention that FDG-PET can differentiate malignancy from benignancy; however, some benign bone tumors present with high FDG accumulation, which increases false positive rates in FDG-PET. FDG accumulation reflects glucose metabolism and thereby FDG-PET can be used for staging malignant bone tumors, which require a large amount of glucose. Combined with conventional studies, such as magnetic resonance imaging (MRI) and scintigraphy, FDG-PET can more accurately decide the staging. Finally, FDG-PET is also applied to evaluate the chemotherapy response of malignant bone tumors and is expected to predict a patient's prognosis and to help to decide appropriate chemotherapy agents.